DOCSLIB.ORG

N22252 Natazia Clinical PREA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
N22252 Natazia Clinical PREA CLINICAL REVIEW Application Type NDA Application Number 22-252 Priority or Standard Standard Submit Date July 6, 2009 PDUFA Goal Date May 6, 2010 Division / Office Division of Reproductive and Urologic Products (DRUP) / Office of Drug Evaluation III (ODE III) Reviewer Name Gerald Willett M.D. Review Completion Date April 28, 2010 Established Name Estradiol valerate / Dienogest (EV/DNG) Trade Name To be determined Therapeutic Class Combination oral contraceptive Applicant Bayer HealthCare Pharmaceuticals Inc. Formulation Oral tablets Dosing Regimen - Days 1-2 (3.0 mg EV) Cycle Days (dose) Days 3-7 (2.0 mg EV + 2.0 mg DNG) Days 8-24 (2.0 mg EV + 3.0 mg DNG) Days 25-26 (1.0 mg EV) Days 27-28 (placebo) Indication Contraception (primary) Heavy and/or prolonged menstrual bleeding (secondary) Intended Population Women of childbearing age Clinical Review Gerald Willett, M.D. NDA 22-252 (EV/DNG) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT....................................... 11 1.1 Recommendation on Regulatory Action ........................................................... 11 1.2 Risk Benefit Assessment.................................................................................. 11 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies... 14 1.4 Recommendations for Postmarket Requirements and Commitments .............. 14 2 INTRODUCTION AND REGULATORY BACKGROUND ...................................... 15 2.1 Product Information .......................................................................................... 15 2.2 Currently Available Treatments for Proposed Indications................................. 15 2.3 Availability of Proposed Active Ingredients in the United States....................... 16 2.4 Important Safety Issues with Consideration to Related Drugs.......................... 17 2.5 Summary of Presubmission Regulatory Activity Related to Submission .......... 17 2.6 Other Relevant Background Information .......................................................... 20 3 ETHICS AND GOOD CLINICAL PRACTICES....................................................... 21 3.1 Submission Quality and Integrity ...................................................................... 21 3.2 Compliance with Good Clinical Practices ......................................................... 22 3.3 Financial Disclosures........................................................................................ 22 4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES ......................................................................................................... 24 4.1 Chemistry Manufacturing and Controls ............................................................ 24 4.2 Clinical Microbiology......................................................................................... 24 4.3 Preclinical Pharmacology/Toxicology ............................................................... 24 4.4 Clinical Pharmacology...................................................................................... 25 4.5 Biostatistics.......................................................................................................... 26 4.6 Interdisciplinary Review Team for QT Studies..................................................... 28 5 SOURCES OF CLINICAL DATA............................................................................ 28 5.1 Tables of Studies/Clinical Trials ....................................................................... 28 5.2 Review Strategy ............................................................................................... 37 5.3 Discussion of Individual Studies/Clinical Trials................................................. 37 5.3.1 Pivotal Study 306660 (Report A35179) for Contraception ............................ 37 5.3.2 Pivotal Study 304742 (Report A39818) for Contraception ............................ 70 5.3.3 Pivotal Study 304004 (Report A35644) for Contraception (Also Cycle Control) ................................................................................................................... 90 5.3.4 Pivotal Study 308960 (Report A29849) for DUB ......................................... 107 5.3.5 Pivotal Study 308961 (Report A42568) for DUB ......................................... 134 5.3.6 Other Studies .............................................................................................. 148 6 REVIEW OF EFFICACY....................................................................................... 186 Efficacy Summary.................................................................................................... 186 6.1 Contraceptive Indication ................................................................................. 186 2 Clinical Review Gerald Willett, M.D. NDA 22-252 (EV/DNG) 6.1.1 Methods ................................................................................................... 186 6.1.2 Demographics.......................................................................................... 187 6.1.3 Subject Disposition .................................................................................. 189 6.1.4 Analysis of Primary Endpoint ................................................................... 189 6.1.5 Analysis of Secondary Endpoints............................................................. 190 6.1.6 Other Endpoints ....................................................................................... 191 6.1.7 Subpopulations ........................................................................................ 191 6.1.8 Analysis of Clinical Information Relevant to Dosing Recommendations .. 191 6.1.9 Discussion of Persistence of Efficacy....................................................... 191 6.1.10 Additional Efficacy Issues/Analyses .......................................................... 191 6.2 Heavy and/or Prolonged Menstrual Bleeding Indication (DUB) ........................ 192 6.2.1 Methods ...................................................................................................... 192 6.2.2 Demographics and Baseline Bleeding Symptoms....................................... 192 6.2.3 Disposition................................................................................................... 193 6.2.4 Analysis of Primary Endpoint ...................................................................... 195 6.2.5 Analysis of Secondary Endpoints (Pooled Analysis) ................................... 199 6.2.6 Other Endpoints .......................................................................................... 204 6.2.7 Subpopulations ........................................................................................... 204 6.2.8 Analysis of Clinical Information Relevant to Dosing Recommendations ..... 204 6.2.9 Discussion of Persistence of Efficacy.......................................................... 204 6.2.10 Additional Efficacy Issues / Analyses ........................................................ 205 6.2.11 Summary of DUB Efficacy......................................................................... 207 7 REVIEW OF SAFETY........................................................................................... 208 Safety Summary ...................................................................................................... 208 7.1 Methods.......................................................................................................... 208 7.1.1 Components of NDA 22-252 Used to Evaluate Safety............................. 208 7.1.2 Categorization of Adverse Events............................................................ 209 7.1.3 Pooling of Data across Studies/Clinical Trials to Estimate and Compare Incidence.................................................................................................. 209 7.2 Adequacy of Safety Assessments .................................................................. 209 7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations................................................................................... 209 7.2.2 Explorations for Dose Response.............................................................. 210 7.2.3 Special Animal and/or In Vitro Testing ..................................................... 210 7.2.4 Routine Clinical Testing ........................................................................... 210 7.2.5 Metabolic, Clearance, and Interaction Workup ........................................ 210 7.2.6 Evaluation for Potential Adverse Events for Similar Drugs in Drug Class 210 7.3 Major Safety Results ...................................................................................... 210 7.3.1 Deaths...................................................................................................... 210 7.3.2 Nonfatal Serious Adverse Events ............................................................ 211 7.3.3 Discontinuations Due to Adverse Events ................................................. 212 7.3.4 Significant Adverse Events ...................................................................... 213 7.3.5 Submission Specific Primary Safety Concerns ........................................ 213 7.4 Supportive Safety Results .............................................................................. 214 3 Clinical Review Gerald Willett, M.D. NDA 22-252 (EV/DNG) 7.4.1 Common Adverse Events .......................................................................
Load more

Recommended publications
  • Gynoid Vs Android Fat Distribution
    Gynoid vs android fat distribution Continue 20-09-2019Biology around the spread of android/ionoid On the DEXA scan you will see that it calculates the ratio of android gyoid. Android is described as the distribution of fat around the middle of the section, so around the waist (navel). Ginoid is the distribution of fat around the thighs, this region is located around the upper thighs. Where you store fat can help determine what type of shape you are and if you are more at risk of increasing visceral fat. If you store more fat around the android area (waist) it is considered the shape of an apple. Android/ginoid ratio of more than 1 will determine this, and you may be at greater risk of having high visceral fat (fat around the organs). If your A/G ratio is smaller than 1 you can see more fat stored around your hips. As a rule, ≤0.8, and males - 1. When a man's body fat % falls on some of the lower ranges it is common for the last bit of fat to be stored around the ginoid area. This ratio can be tracked over time to see if the fat is predominantly lost near one area or both. Where you store/distribute fat can also be transmitted through genetics, so it can be difficult to detect train certain areas. Biology! Android fat cells are predominantly visceral, they are large fat cells deposited under the skin and very metabolically active. The hormones they secrete have direct access to the liver, you may have heard of the term fatty liver.
    [Show full text]
  • Body Fat Distribution As a Risk Factor for Osteoporosis
    SAMJ I ARTICLES In the past, most epidemiological studies that examined Body fat distribution as a the association between obesity and disease considered only total adipose tissue and ignored its distribution. risk factor for osteoporosis Recently it has become apparent that it is not obesity per se, but the regional distribution of adipose tissue, that Renee Blaauw, Eisa C. Albertse, Stephen Hough correlates with many obesity-related morbidities including atherosclerosis, hypertension, hyperlipidaemias and 4 diabetes mellitus. -8 Objective. The aim of this study was to compare the body The anatomical distribution of adipose tissue differs fat distribution of patients with osteoporosis (GP) with that between men and women in both normal and obese of an appropriately matched non-GP control group. individuals, suggesting that sex hormones are involved in Design. Case control study. the regulation of adipose tissue metabolism.5--10 Upper body Setting. Department of Endocrinology and Metabolism, (android or waist) obesity, which is typically observed in men, is associated with hyperandrogenism, whereas lower Tygerberg Hospital. body (gynoid or hip) obesity is far more common in women, Participants. A total of 56 patients with histologicatly suggesting an oestrogenic influence.':>-12 Moreover, upper proven idiopathic GP, of whom 39 were women (mean age body obesity has been shown to be associated with 61 ± 11 years) and 17 men (49 ± 15 years), were compared hypercortisolism and classically occurs in patients with with 125 age- and sex-matched non-OP (confirmed by Cushing's syndrome. 13 Since hypogonadism and dual energy X-ray absorptiometry) subjects, 98 women hypercortisolaemia are well-known causes of GP, we questioned whether this disease was also associated with (60 ± 11 years) and 27 men (51 ± 16 years).
    [Show full text]
  • A Large-Scale Genome-Wide Interaction Study Llida Barata Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2015 The influence of age and sex on genetic associations with adult body size and shape: A large-scale genome-wide interaction study Llida Barata Washington University School of Medicine in St. Louis Mary F. Feitosa Washington University School of Medicine in St. Louis Jacek Czajkowski Washington University School of Medicine in St. Louis Jeannette Simino Washington University School of Medicine in St. Louis Pamela A. F. Madden Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Barata, Llida; Feitosa, Mary F.; Czajkowski, Jacek; Simino, Jeannette; Madden, Pamela A. F.; Sung, Yun Ju; Heath, Andrew C.; Rice, Treva K.; Rao, D. C.; and et al., ,"The influence of age and sex on genetic associations with adult body size and shape: A large-scale genome-wide interaction study." PLoS Genetics.11,10. e1005378. (2015). https://digitalcommons.wustl.edu/open_access_pubs/4605 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Llida Barata, Mary F. Feitosa, Jacek Czajkowski, Jeannette Simino, Pamela A. F. Madden, Yun Ju Sung, Andrew C. Heath, Treva K. Rice, D. C. Rao, and et al. This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/4605 RESEARCH ARTICLE The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study Thomas W.
    [Show full text]
  • Editor's Pick
    EDITOR’S PICK In women of reproductive age, polycystic ovary syndrome (PCOS) is one of the most common abnormalities, and obesity is observed in about 80% of these patients. The relationship between PCOS and obesity is complex, and therefore the study “Selection of Appropriate Tools for Evaluating Obesity in Polycystic Ovary Syndrome Patients” is very welcome. The author concludes that using BMI to diagnose and classify obesity, a high fat content, or fat distribution of android type in PCOS patients with normal weight can be overlooked. Prof Joep Geraedts SELECTION OF APPROPRIATE TOOLS FOR EVALUATING OBESITY IN POLYCYSTIC OVARY SYNDROME PATIENTS *Yang Xu Reproductive and Genetic Medical Center, Peking University First Hospital; OB/GYN Department, Peking University First Hospital, Beijing, China *Correspondence to [email protected] Disclosure: The author has declared no conflicts of interest. Received: 02.05.17 Accepted: 06.07.17 Citation: EMJ Repro Health. 2017;3[1]:48-52. ABSTRACT Patients with polycystic ovary syndrome (PCOS) have unique endocrine and metabolic characteristics, whereby the incidence and potentiality of obesity, as well as the accompanying risk of metabolic and cardiovascular diseases, are significantly increased. Currently, BMI is widely used to diagnose and classify obesity. However, body fat is not accounted for in BMI calculations, and the missed diagnosis rate of obesity is nearly 50%. Since PCOS patients with normal weight are also characterised by a high content of fat or fat distribution of android type, some of these patients are often overlooked if an inappropriate diagnostic tool for obesity is selected, which affects the therapeutic effect. Herein, we have reviewed the mechanism and diagnostic methods of PCOS-related obesity and suggested that not only body weight and circumference alone, but also the body fat percentage and fat distribution, should be considered for the evaluation of obesity in PCOS patients.
    [Show full text]
  • Effective Measures of Weight Gain Five Years Post-Kidney Transplantation
    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 12-2018 Effective Measures of Weight Gain Five Years Post- Kidney Transplantation Tara Calico Cherry University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Cardiovascular Diseases Commons, Endocrine System Diseases Commons, Investigative Techniques Commons, Nutritional and Metabolic Diseases Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, and the Other Nursing Commons Recommended Citation Cherry, Tara Calico (http://orcid.org/ https://orcid.org/0000-0002-2069-1836), "Effective Measures of Weight Gain Five Years Post- Kidney Transplantation" (2018). Theses and Dissertations (ETD). Paper 468. http://dx.doi.org/10.21007/etd.cghs.2018.0471. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Effective Measures of Weight Gain Five Years Post-Kidney Transplantation Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Nursing Science Research Advisor Donna K. Hathaway Ph.D Committee Carolyn J. Graff, Ph.D. Carrie Harvey, Ph.D. Tara O’Brien, Ph.D. George E. Relyea, MS ORCID http://orcid.org/ https://orcid.org/0000-0002-2069-1836 DOI 10.21007/etd.cghs.2018.0471 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/468 Effective Measures of Weight Gain Five Years Post-Kidney Transplantation A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Tara Calico Cherry December 2018 Copyright © 2018 by Tara Calico Cherry.
    [Show full text]
  • A Guide to Obesity and the Metabolic Syndrome
    A GUIDE TO OBESITY AND THE METABOLIC SYNDROME ORIGINS AND TREAT MENT GEORG E A. BRA Y Louisiana State University, Baton Rouge, USA Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business © 2011 by Taylor and Francis Group, LLC CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2011 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number: 978-1-4398-1457-4 (Hardback) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the valid- ity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or uti- lized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopy- ing, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
    [Show full text]
  • High Baseline Fat Mass, but Not Lean Tissue Mass, Is Associated with High Intensity Low Back Pain and Disability in Community-Based Adults Sharmayne R
    Brady et al. Arthritis Research & Therapy (2019) 21:165 https://doi.org/10.1186/s13075-019-1953-4 RESEARCH ARTICLE Open Access High baseline fat mass, but not lean tissue mass, is associated with high intensity low back pain and disability in community-based adults Sharmayne R. E. Brady†, Donna M. Urquhart*†, Sultana Monira Hussain, Andrew Teichtahl, Yuanyuan Wang, Anita E. Wluka and Flavia Cicuttini Abstract Objectives: Low back pain is the largest contributor to disability worldwide. The role of body composition as a risk factor for back pain remains unclear. Our aim was to examine the relationship between fat mass and fat distribution on back pain intensity and disability using validated tools over 3 years. Methods: Participants (aged 25–60 years) were assessed at baseline using dual-energy X-ray absorptiometry (DXA) to measure body composition. All participants completed the Chronic Pain Grade Scale at baseline and 3-year follow-up. Of the 150 participants, 123 (82%) completed the follow-up. Results: Higher baseline body mass index (BMI) and fat mass (total, trunk, upper limb, lower limb, android, and gynoid) were all associated with high intensity back pain at either baseline and/or follow-up (total fat mass: multivariable OR 1.05, 95% CI 1.01–1.09, p < 0.001). There were similar findings for all fat mass measures and high levels of back disability. A higher android to gynoid ratio was associated with high intensity back pain (multivariable OR 1.04, 95% CI 1.01–1.08, p = 0.009). There were no associations between lean mass and back pain.
    [Show full text]
  • Android Fat Deposition and Its Association with Cardiovascular Risk Factors in Overweight Young Males
    fphys-10-01162 September 14, 2019 Time: 12:26 # 1 ORIGINAL RESEARCH published: 18 September 2019 doi: 10.3389/fphys.2019.01162 Android Fat Deposition and Its Association With Cardiovascular Risk Factors in Overweight Young Males Carolina Ika Sari1, Nina Eikelis1,2, Geoffrey A. Head3, Markus Schlaich4, Peter Meikle5, Gavin Lambert1,2 and Elisabeth Lambert1,2* 1 Human Neurotransmitters Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia, 2 Iverson Health Innovation Research Institute, School of Health Sciences, Faculty of Health, Arts and Design, Swinburne University of Technology, Hawthorn, VIC, Australia, 3 Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia, 4 Dobney Hypertension Centre, School of Medicine – Royal Perth Hospital Unit, The University of Western Australia, Perth, WA, Australia, 5 Metabolomics Laboratories, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia Objective: Excess adiposity increases the risk of type-2 diabetes and cardiovascular disease development. Beyond the simple level of adiposity, the pattern of fat distribution may influence these risks. We sought to examine if higher android fat distribution was associated with different hemodynamic, metabolic or vascular profile compared to a Edited by: lower accumulation of android fat deposits in young overweight males. Jean-Pierre Montani, Université de Fribourg, Switzerland Methods: Forty-six participants underwent dual-energy X-ray absorptiometry and were Reviewed by: stratified into two groups. Group 1: low level of android fat (<9.5%) and group 2: high Ashraf S. Gorgey, Hunter Holmes McGuire VA Medical level of android fat (>9.5%). Assessments comprised measures of plasma lipid and Center, United States glucose profile, blood pressure, endothelial function [reactive hyperemia index (RHI)] and Alfonso Bellia, muscle sympathetic nerve activity (MSNA).
    [Show full text]
  • Clinical Study Effects of Resistance Training and Soy Isoflavone On
    Hindawi Publishing Corporation Obstetrics and Gynecology International Volume 2010, Article ID 156037, 8 pages doi:10.1155/2010/156037 Clinical Study Effects of Resistance Training and Soy Isoflavone on Body Composition in Postmenopausal Women Fabio´ Lera Orsatti,1, 2, 3 Eliana Aguiar Petri Nahas,1 Jorge Nahas-Neto,1 Nailza Maesta,2 Claudio´ Lera Orsatti,1 and Cesar Edurado Fernandes4 1 Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University, Rubiao Junior, Botucatu, Sao Paulo 18618-970, Brazil 2 Department of Public Health, Center of Nutrition and Exercise Metabolism, Botucatu Medical School, Sao Paulo State University, Rubiao Junior, Sao Paulo 18618-970, Brazil 3 School of Physical Education, Federal University of Triangulo Mineiro (UFTM), Uberaba, Minas Gerais 38025-180, Brazil 4 Department of Gynecology and Obstetrics, ABC Medical School, Sao Paulo 09060-870, Brazil Correspondence should be addressed to Fabio´ Lera Orsatti, [email protected] Received 9 November 2009; Revised 10 January 2010; Accepted 3 March 2010 Academic Editor: Marc L’Hermite Copyright © 2010 Fabio´ Lera Orsatti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To investigate the independent and additive effects of resistance training (RT) and soy isoflavone (ISO) on body composition in postmenopausal women (PW). Method. This study used a placebo-controlled, double-blind (soy), randomized (ISO versus placebo) × (RT versus No RT) design. A total of 80 PW, aged 45–70 years, were randomly (71 completed 9-months intervention): RT + ISO (n = 15), No RT + ISO (n = 20), RT + placebo (n = 18), and No RT + placebo (n = 18).
    [Show full text]
  • Regular Posters (PDF, 1.75 Mb | 116 Pages)
    Regular Posters 17 POSTER SESSION 1: HOMAIR: 2.78 ± 0.34 vs 1.02 ±0.17, p< 0.01) was present in android obese hypertensive patients compared to gynoid respectively; despite an absence of dyslipidaemia (TC: 164.98 ± 4.56 vs 154.56 ± 4.71 mg/dL, p > 0.05 ; LDLC: 115.00 ± 4.96 vs 90.12 ± 4.6, p< 0.01) leading to absence of atherosclerosis(p> 0.05) (LDLC/HDLC: 3.94 ± 0.59 vs 3.13 ± 2.77). Conclusion: Cameroonians Abdominal obesity/Body fat distribution are healthy metabolic obese as far as lipid profile and Na+/K+ homeostasis are concerned even when suffering from hypertension. This information could be useful in helping to shape treatment to obesity induced hypertension among 530 Cameroonian. REPORTED DIABETES: INCIDENCE AND PREDICT IN COHORT ELDERLY PEOPLE, RESIDENT IN THE CITY OF SÃO PAULO - SABE SURVEY M.F. Almeida, M.F.N. Marucci, L.A. Gobbo, D.A.Q.S. Dourado 282 Departamento de Nutrição, Faculdade de Saúde Pública - FSP/ Universidade ASSESSMENT THE WAIST CIRCUNFERENCE CUTOFF OBTAINED IN de São Paulo - USP, São Paulo, Brazil ADOLESCENTS OF A CITY ARGENTINA Introduction: The incidence of diabetes mellitus (DM) has increased, mainly in W.R. Pedrozo, G.A. Bonneau, M.S. Castillo Razcón aged persons. Epidemiological evidences show that obesity and abdominal fat Laboratorio Central, Hospital 'Dr Ramón Madariaga', Posadas, Argentina constitute risk factor for development of DM. Objective: To verify the Objective: Identify and assess the value of the 90th percentile of waist association the incidence of DM with obesity and abdominal fat, in cohort of circumference (WC) in adolescents Posadas Misiones Argentina.
    [Show full text]
  • Use of Murinometrics Indices and Bioelectrical Impedance (BIA) in the Determination of Experimental Obesity in Oophorectomized Rats
    Acta Scientiarum http://www.uem.br/acta ISSN printed: 1679-9283 ISSN on-line: 1807-863X Doi: 10.4025/actascibiolsci.v38i4.31714 Use of murinometrics indices and bioelectrical impedance (BIA) in the determination of experimental obesity in oophorectomized rats Alex Soares Marreiros Ferraz1*, Ruan Carlos Macêdo de Moraes2, Naiza Arcângela Ribeiro de Sá3, Francisco Teixeira Andrade4, Maria do Carmo de Carvalho e Martins4 and Vânia Marilande 3 Ceccatto 1Instituto de Educação Física e Esportes, Universidade Federal do Ceará, Campus do Pici, Av Mister Hull, s/n, Parque Esportivo, Bloco 320, 60455-760, Fortaleza, Ceará, Brazil. 2Programa de Pós-graduação em Fisiologia Humana, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, São Paulo, Brazil. 3Programa de Pós-graduação em Ciências Fisiológicas, Instituto Superior de Ciências Biomédicas, Universidade Estadual do Ceará, Fortaleza, Ceará, Brazil. 4Departamento de Biofísica e Fisiologia, Universidade Federal do Piauí, Teresina, Piauí, Brazil. *Author for correspondence. E-mail: [email protected] ABSTRACT. In this study, we tested the use of murinometric indices and bioimpedance (BIA) to determine obesity in rats. Female Wistar rats (8 weeks/130-160 g) were divided into control and oophorectomy group. The Body Mass Index (BMI) and Lee index (LI) were used as anthropometric techniques to determine obesity, and the determination of body composition by BIA, as a way to partition body weight into fat mass and lean mass components. The dissection of muscle tissues and adipose deposits was used as a direct determination of body fat content. The groups had body weight gain (p <0.05) after the trial period, with a differential gain in body fat (p <0.05) observed by the dissection of tissue in the oophorectomy group.
    [Show full text]
  • PAPER Effects of Hormone Replacement Therapy on Weight, Abdominal Fat Distribution, and Lipid Levels in Japanese Postmenopausal Women
    International Journal of Obesity (2003) 27, 1044–1051 & 2003 Nature Publishing Group All rights reserved 0307-0565/03 $25.00 www.nature.com/ijo PAPER Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women H Sumino1*, S Ichikawa2, A Yoshida3, M Murakami3, T Kanda4, H Mizunuma5, T Sakamaki6 and M Kurabayashi1 1Second Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan; 2Cardiovascular Hospital of Central Japan, Gunma, Japan; 3Department of Laboratory Medicine, Gunma University School of Medicine, Maebashi, Japan; 4Department of General Medicine, Kanazawa Medical University, Kanazawa, Japan; 5Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Japan; and 6Medical Informatics and Decision Sciences, Gunma University School of Medicine, Maebashi, Japan OBJECTIVE: To investigate the effects of hormone replacement therapy (HRT) on weight, abdominal fat distribution, and fasting lipid levels in Japanese postmenopausal women (PMW). DESIGN: Prospective, 12-month-controlled clinical comparison of women with and without HRT. SUBJECTS: In all, 35 PMW with HRT (conjugated estrogens, 0.625 mg daily; medroxyprogesterone acetate, 2.5 mg daily; HRT group) and 26 PMW without HRT (control group). MEASUREMENTS: Weight, abdominal fat distribution by computed tomographic measurements, lipid profiles, and sex hormones were determined at baseline and after 12 months of treatment or observation. RESULTS: Weight did not change in any group. Visceral abdominal fat increased in controls, but not in the HRT group. Total and low-density lipoprotein cholesterol decreased, and triglyceride (TG) and high-density lipoprotein cholesterol increased in the HRT group; these did not change in the control group.
    [Show full text]